Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ACC, SRP

New Date for Sectra's Nine-month Interim Report 2017/2018


LINKÖPING, Sweden, Nov. 1, 2017 /PRNewswire/ -- The Board of Directors of international medical imaging IT and cybersecurity company Sectra (SECT-B.ST) has decided to change the publication date of the company's nine-month interim report for the 2017/2018 fiscal year. The new date is Monday, March 12, 2018, at 8:00 a.m. (previous planned publication date was March 6, 2018).

The change was made due to the fact that the original report date coincides with important industry trade fairs that management need to attend. 

Sectra's financial reporting calendar 

December 8, 2017, 8:00 a.m. (CET): Six-month interim report

December 8, 2017, 10:00 a.m. (CET): Teleconference/Presentation of Sectra's six-month report

March 12, 2018, 8:00 a.m. (CET): Nine-month interim report

May 29, 2018, 8:00 a.m. (CET): Year-end report 2017/2018:

For more information about Sectra's financial events and reports: http://www.sectra.com/investor/calendar/

Subscribe for information
To subscribe for financial reports, invitations and information from Sectra via e-mail, please fill in your contact information at www.sectra.com/prenumerera.

This information constitutes information that Sectra AB (publ) is obliged to make public. The information was submitted to the media for publication, through the agency of the contact person set out below, at 8:20 a.m. (CET) on November 1, 2017.

For further information, please contact:
Dr. Torbjörn Kronander
CEO and President
Sectra AB
+46(0)705-23-52-27

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/sectra/r/new-date-for-sectra-s-nine-month-interim-report-2017-2018,c2379641

The following files are available for download:

http://mb.cision.com/Main/1263/2379641/744357.pdf

PDF


These press releases may also interest you

at 02:10
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the...

at 02:00
Exams can be daunting for students and parents, but with the right approach it can become a rewarding and manageable experience. Expert private tutors can support academic study and exam-readiness while promoting students' mental health with...

at 02:00
As part of its Global Science Summit, the Novo Nordisk Foundation issues an international open call for research projects to catalyse science-based solutions to key global challenges. The programme expects to hand out up to eight grants with a total...

at 02:00
"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its...

at 01:27
GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual...

at 01:05
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business...



News published on and distributed by: